MEDISPA.PRO
Ministry of Health code: A25.24.001.002 Axis M7 · Neuroplasticity and stress adaptation CEBM: Level A (Injection methods)

Medically indicated botulinum therapy (migraine, spasticity, hyperhidrosis, bruxism)

Therapeutic Botulinum Toxin Injections

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
30 min
Turnover: ~45 min
Recommended course
1 sessions
1 treatments – an assumption for the economic calculation; the course is prescribed by a physician
Throughput capacity
11 pts
per 8-hour shift
Median rate
42 900 ₽
22 275 ₽ – 58 950 ₽
Course cost
42 900 ₽
at market median
Publication volume
Level A
7 publ. in PubMed

Clinical profile

Injections of botulinum toxin type A for neurological and other medical indications. An effect has been shown in chronic migraine (Cochrane, PREEMPT) and limb spasticity (level A), in axillary hyperhidrosis and bruxism; for episodic migraine and TMJ disorders, study results do not yet favour the method.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Where studies show an effect

  • Chronic migraine prevention: on average 2 fewer migraine days per month than on placebo; less disability. [1, 2]
  • Upper and lower limb spasticity in adults: efficacy established (level A). [3]
  • Axillary hyperhidrosis: moderate-quality evidence in favour of botulinum toxin. [4]
  • Bruxism, especially severe: effective and safe treatment. [5]

Open questions and study limitations

  • Episodic migraine and chronic tension-type headache: the 2016 AAN guideline found no demonstrated effect. [3]
  • Temporomandibular joint disorders: a 2024 meta-analysis found no advantage for pain or mouth opening. [6]

Safety

  • Non-serious side effects in migraine: 60 in 100 patients versus 47 in 100 on placebo. [1]
  • Neutralising antibodies develop in 0.49 % of patients; loss of treatment response due to them is rare. [7]
Contraindications. Contraindications are determined by the physician according to the equipment or drug instructions; they are not given in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
Injection kit, botulinum toxin type A preparation

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
Injection kit
Medical device, Roszdravnadzor registration certificate / CE
In the registry →
botulinum toxin type A preparation
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.1.1 20.0 m² · Class B/V

Neurologist's consulting room

Physicians' consulting and examination rooms · Equipment: 3 183 500 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) 22 275 ₽
Market median 42 900 ₽
75th percentile (P75) 58 950 ₽

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Prices for this procedure appear in the price lists of 3 industry facilities; the median and interquartile range across facilities are shown (each facility counts once).

Evidence base

In chronic migraine and spasticity, a Cochrane review and level A recommendations; for other indications the evidence is weaker.

Publication level A · Plenty of data
  1. 1.
    Botulinum toxins for the prevention of migraine in adults.
    Cochrane Database Syst Rev, 2018 · Cochrane systematic review · PMID 29939406
    Chronic migraine: 2 fewer migraine days per month than placebo; non-serious side effects in 60 in 100 versus 47 in 100.
  2. 2.
    OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Headache, 2010 · Pooled analysis of the PREEMPT RCTs · PMID 20487038
    Chronic migraine: effective prevention, less headache-related disability.
  3. 3.
    Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Neurology, 2016 · AAN guideline (later retired) · PMID 27164716
    Upper and lower limb spasticity: level A; chronic migraine: level A; no effect shown for episodic migraine.
  4. 4.
    Interventional management of hyperhidrosis in secondary care: a systematic review.
    Br J Dermatol, 2018 · Systematic review · PMID 29573391
    Axillary hyperhidrosis: moderate-quality evidence in favour of botulinum toxin.
  5. 5.
    Efficacy of botulinum toxin in the treatment of bruxism: Systematic review.
    Med Oral Patol Oral Cir Bucal, 2019 · Systematic review · PMID 31246937
    Bruxism: safe and effective treatment, especially in severe bruxism.
  6. 6.
    The effectiveness of botulinum toxin for temporomandibular disorders: A systematic review and meta-analysis.
    PLoS One, 2024 · Systematic review and meta-analysis · PMID 38483856
    TMJ disorders: in this meta-analysis results were comparable with control for pain, mouth opening and bruxism.
  7. 7.
    Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
    Mov Disord, 2010 · Meta-analysis · PMID 20737546
    Neutralising antibody formation in 0.49 % of patients; clinical loss of treatment response in three.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.